within Pharmacolibrary.Drugs.S_SensoryOrgans.S01A_Antiinfectives.S01AA10_Natamycin;

model Natamycin
  extends Pharmacolibrary.Drugs.ATC.S.S01AA10;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>S01AA10</td></tr><td>route:</td><td>ophthalmic</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Natamycin is a polyene antifungal agent used primarily for the treatment of fungal infections of the eye, such as fungal keratitis, blepharitis, and conjunctivitis. It is topically applied and acts by binding to ergosterol in fungal cell membranes, leading to increased membrane permeability and cell death. Natamycin is approved by regulatory agencies such as the FDA for ophthalmic use and is not used systemically due to its poor absorption through intact epithelium.</p><h4>Pharmacokinetics</h4><p>There are no human pharmacokinetic (PK) studies that report systemic PK parameters for natamycin following ophthalmic administration due to its minimal systemic absorption. Published data indicate that natamycin remains localized in ocular tissues and is not detected at significant levels in plasma. Therefore, no compartmental PK parameters are available.</p><h4>References</h4><ol><li><p>Zhao, X, et al., &amp; Lu, H (2018). Comparison of the Ocular Penetration and Pharmacokinetics Between Natamycin and Voriconazole After Topical Instillation in Rabbits. <i>Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics</i> 34(6) 460–467. DOI:<a href=\"https://doi.org/10.1089/jop.2017.0139\">10.1089/jop.2017.0139</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29792548/\">https://pubmed.ncbi.nlm.nih.gov/29792548</a></p></li><li><p>Bhatta, RS, et al., &amp; Shukla, PK (2012). Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: In vitro and pharmacokinetics studies. <i>International journal of pharmaceutics</i> 432(1-2) 105–112. DOI:<a href=\"https://doi.org/10.1016/j.ijpharm.2012.04.060\">10.1016/j.ijpharm.2012.04.060</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22569234/\">https://pubmed.ncbi.nlm.nih.gov/22569234</a></p></li><li><p>Velpandian, T, et al., &amp; Halder, N (2021). Novel water soluble sterile natamycin formulation (Natasol) for fungal keratitis. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 163 105857–None. DOI:<a href=\"https://doi.org/10.1016/j.ejps.2021.105857\">10.1016/j.ejps.2021.105857</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33882328/\">https://pubmed.ncbi.nlm.nih.gov/33882328</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Natamycin;
